Phase II dose-finding study of balugrastim in breast cancer patients receiving myelosuppressive chemotherapy
Crossref DOI link: https://doi.org/10.1007/s12032-015-0623-x
Published Online: 2015-05-13
Published Print: 2015-06
Update policy: https://doi.org/10.1007/springer_crossmark_policy
Gladkov, Oleg
Moiseyenko, Vladimir
Bondarenko, Igor N.
Shparyk, Yaroslav
Barash, Steven
Adar, Liat
Bias, Peter
Avisar, Noa
Funding for this research was provided by:
Teva Branded Pharmaceutical Products R & D, Inc.
Text and Data Mining valid from 2015-05-13